AMC 036: A PHASE II TRIAL OF TOPICAL HALOFUGINONE IN PATIENTS WITH HIV RELAT

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者的研究机构。 具体目标 主要终点： 1. 确定局部用常山酮与溶媒对照治疗艾滋病相关卡波西肉瘤的肿瘤反应率。 2. 评价局部用常山酮和赋形剂治疗艾滋病相关卡波西肉瘤患者的安全性和耐受性。 次要终点： 1. 确定局部用常山酮抑制艾滋病相关卡波西肉瘤中MMP-2和I型胶原表达的能力。 2. 探讨基线CD 4和CD 8计数、HIV病毒载量和HHV-8病毒载量与常山酮疗效的关系。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. SPECIFIC AIMS Primary Endpoints: 1. To determine the tumor response rate of AIDS-related Kaposi's sarcoma to topical halofuginone versus vehicle control. 2. To evaluate the safety and tolerability of topical halofuginone and vehicle patients with AIDS-related Kaposi's sarcoma. Secondary Endpoints: 1. To determine the ability of topical halofuginone to inhibit expression of MMP-2 and Collagen type I in AIDA-related Kaposi's sarcoma. 2. To explore the relationship between baseline CD4 and CD8 counts, HIV viral load and HHV-8 viral load and response to halofuginone.